The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1735
August 18, 2025
View Complete Issue         Table of Contents 2019 
Mepolizumab (Nucala) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Mepolizumab (Nucala) for COPD
August 18, 2025 (Issue: 1735)
Mepolizumab (Nucala – GSK), a subcutaneously injected interleukin-5 (IL-5) antagonist, has been approved by the FDA for add-on maintenance treatment of adults who have inadequately controlled chronic obstructive pulmonary disease (COPD) with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Mepolizumab (Nucala) for COPD
Article code: 1735b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.